Trials / Recruiting
RecruitingNCT06415669
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of Paclitaxel (Albumin-bound) Combined With Apatinib and Adebrelimab in the Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma Following Previous Immunotherapy Progression
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma following the progression of previous immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel for injection (albumin-bound) | 100 mg/m2, day 1, day 8, every 21 days for a cycle. |
| DRUG | Adebrelimab | 20mg/kg or 1200mg, the first day, every 21 days as a cycle. |
| DRUG | Apatinib mesylate | 250mg once a day for 5 consecutive days and discontinue for 2 days |
Timeline
- Start date
- 2024-05-19
- Primary completion
- 2026-05-19
- Completion
- 2027-05-19
- First posted
- 2024-05-16
- Last updated
- 2024-05-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06415669. Inclusion in this directory is not an endorsement.